Generex, immer wieder Generex! - 500 Beiträge pro Seite

[mattvan]

Vogelgrippe-Zeit steht vor der Tür, die Gesundheitsorganisationen warnen bereits wieder. Wer erinnert sich nicht an letztes Jahr, wo die Aktie durch die Decke schoss. Begleitet von nur guten Meldungen ist diese Aktie auch in anderen seht interessanten Bereichen tätig und berichtet ausschließlich über positive Ergebnisse bzw. Vorstudien. Gestern wieder zwei hoffenden Meldungen, für mich ist diese Aktie deutlich unterbewertet und wartet nur darauf, endlich abzugehen.

Home
Investing
News & Opinion
Retirement
Banking & Credit
Loans
Insurance
Small Biz
Special Editions
Columnists
Personal Finance
Investing Ideas
Markets
Company Finances
Providers
Get Quotes


Symbol Lookup
Finance Search

Press Release Source: Generex Biotechnology

Generex Biotechnology Publishes Studies Demonstrating Anti-Tumor Potential of Immunotherapeutic Vaccine
Tuesday October 3, 7:00 am ET

TORONTO--(MARKET WIRE)--Oct 3, 2006 -- Generex Biotechnology Corporation (NASDAQ:GNBT - News) announced today publication of studies demonstrating specific anti-tumor activity of its novel Ii-Key/HER-2/neu immunotherapeutic vaccine. The studies were performed in the laboratory of Dr. Costas Baxevanis in collaboration with scientists at Antigen Express, the immunotherapeutic division of Generex Biotechnology.
ADVERTISEMENT

The results of the recent efforts appear in the journal Cancer Immunology and Immunotherapy under the title "Ii-Key/HER-2/neu(776-790) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumors." In addition to demonstrating increased activity in human lymphyocyte cultures of peptides designed with the proprietary Ii-Key modification, the studies also demonstrate the anti-tumor efficacy of these activated lymphocytes in suppressing the growth of human ovarian cancer cells (expressing HER-2/neu) in an animal model. Further, mechanistic studies demonstrated that the specifically stimulated lymphocytes worked by enhancing the activity of cytotoxic T lymphocytes (CTLs), which is consistent with the proposed mechanism of action of lymphocytes stimulated by Ii-Key/Her-2/neu hybrid peptides.

"The studies complement nicely the ongoing clinical trials of the Ii-Key/HER-2/neu hybrid peptide AE37 in breast cancer patients," said Eric von Hofe, President of Antigen Express. "We have seen activation of lymphocytes from AE37 immunized patients similar to the activation of lymphocytes observed in the recently published studies. Taken together, these observations provide real encouragement as to the clinical utility of Ii-Key hybrids such as AE37."

In addition to developing an immunotherapeutic vaccine for HER-2/neu expressing cancers, Antigen Express is also developing vaccines for other types of cancer and infectious diseases, including the potentially pandemic H5N1 influenza virus. The fact that Antigen Express vaccines are manufactured by an entirely synthetic process, enabling rapid production of large amounts, makes them uniquely suited for an H5N1 vaccine given the likely demand for such a vaccine and the supply limitations of more traditional vaccines.

About Generex

Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Generex Oral-lyn(TM)), which is available for sale in Ecuador for the treatment of patients with Type 1 and Type 2 diabetes, is in various stages of clinical trials around the world. For more information, visit the Generex Web site at www.generex.com.

Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.


Contact:
Contacts:

Shayne Gilliatt
Generex Biotechnology Corporation
Phone: [phone]
or [phone]

Andrew Hellman
CEOcast, Inc.
Phone: [phone]

Dolores Naney
Rubenstein Public Relations
Phone: [phone]

Source: Generex Biotechnology

Home
Investing
News & Opinion
Retirement
Banking & Credit
Loans
Insurance
Small Biz
Special Editions
Columnists
Personal Finance
Investing Ideas
Markets
Company Finances
Providers
Get Quotes


Symbol Lookup
Finance Search

AP
Generex Cancer Drug Trials Encouraging
Tuesday October 3, 10:05 am ET
Generex Publishes Promising Vaccine Data for Treatment of Ovarian Cancer

NEW YORK (AP) -- Biotech drug maker Generex Biotechnology Corp. said Tuesday a medical journal published promising lab test results of its cancer vaccine for the treatment of ovarian cancer.
The company showed its cancer vaccine suppressed the growth of human cancer cells in an animal study published in the journal Cancer Immunology and Immunotherapy.

The vaccine is centered around compounds called Ii-Key/HER-2/neu hybrid peptides.

The company said the results mesh with ongoing clinical trials studying a similar compound for the treatment of breast cancer.

Shares of Generex rose 7 cents to $1.72 in morning trading on the Nasdaq.

[Stilcom]

Antwort auf Beitrag Nr.: 24.392.530 von mattvan am 04.10.06 09:51:18

News
GNBT -- Generex Biotechnology Corp.
Com ($0.001)

COMPANY NEWS AND PRESS RELEASES FROM OTHER SOURCES:
Generex Biotechnology Announces Glucose RapidSpray(TM) Product to Be Available at Shoppers Drug Mart(R)

TORONTO, Oct 04, 2006 (MARKET WIRE via COMTEX) -- Generex Biotechnology Corporation (NASDAQ: GNBT), the leader in metabolic diseases drug delivery through the inner lining of the mouth, announced today that the Company's new Glucose RapidSpray(TM) product will be available in Shoppers Drug Mart(R) stores across Canada (Pharmaprix(R) in Quebec) in late October, 2006.

Shoppers Drug Mart is Canada's largest retail drug store group with more than 960 retail drug stores. With fiscal 2005 sales of $7.2 billion, Shoppers Drug Mart is the leading player in Canada's retail drugstore marketplace and is the number one provider of pharmacy products and services. Shoppers Drug Mart stores are located in prime locations in each province and two territories, making Shoppers Drug Mart stores among the most convenient retail outlets in Canada.

Glucose RapidSpray is an innovative alternative for people who require or want additional glucose in their diet. Glucose RapidSpray delivers a fat-free, low-calorie glucose formulation that was developed using the Company's proprietary buccal drug delivery technologies. Glucose RapidSpray delivers glucose directly into the mouth. Glucose RapidSpray is simple to carry and use, with no large tablets to chew or messy gels to swallow.

About Generex

Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Generex Oral-lyn(TM)), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. For more information, visit the Generex Web site at www.generex.com.

Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Contacts:

Shayne Gilliatt
Generex Biotechnology Corporation
Phone: [phone]
or [phone]

Andrew Hellman
CEOcast, Inc.
Phone: [phone]

Dolores Naney
Rubenstein Public Relations
Phone: [phone]
Contact via http://www.marketwire.com/mw/emailprcntct?id=283896096801479…


SOURC

[HerMitDerMillion]

SK USA: 1,8 USD

entspricht 1,417 EUR :-)